Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma

Cancer Chemotherapy and Pharmacology
J A AjaniK Nishioka

Abstract

A total of 32 evaluable patients with measurable advanced colorectal carcinoma were treated with continuous-infusion alpha-difluoromethylornithine (DFMO) at a median daily dose of 8 g/m2 (range, 6-14 g/m2). DFMO was infused over 24 h daily for 28 days, followed by a rest period of 7 days. Of the 32 patients, 14 had received no prior chemotherapy. A total of 65 courses was given, with the median being 2 (range, 1-9 courses). None of the patients achieved a partial or complete response; however, 3 patients achieved a minor response and 14 had stable disease. The frequent toxic effects of DFMO included thrombocytopenia (which was dose-limiting), malaise, nausea, vomiting, reversible hearing loss, and diarrhea. Our data suggest that continuous-infusion DFMO therapy is feasible and results in only mild gastrointestinal toxicity. Although DFMO proved to be ineffective as a single agent in this trial, it could probably best be used in combination with cytotoxic agents known to enhance its antitumor activity in a preclinical setting.

References

Jan 1, 1979·Perspectives in Biology and Medicine·H G Williams-Ashman, Z N Canellakis
Jan 1, 1986·European Journal of Cancer & Clinical Oncology·T A Splinter, J C Romijn
Mar 1, 1986·The Biochemical Journal·A E Pegg
Jan 1, 1985·Investigational New Drugs·A M MaddoxE J Freireich
Jan 1, 1984·Annual Review of Biochemistry·C W Tabor, H Tabor
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G D LukS B Baylin
Mar 1, 1984·Clinical Pharmacology and Therapeutics·A Sjoerdsma, P J Schechter
Feb 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M D AbeloffS B Baylin
Nov 1, 1982·The American Journal of Physiology·A E Pegg, P P McCann

❮ Previous
Next ❯

Citations

Jan 1, 1992·Pharmacology & Therapeutics·P P McCann, A E Pegg
Jan 1, 2003·The Surgical Clinics of North America·Ernest T HawkJaye L Viner
May 27, 2005·World Journal of Gastroenterology : WJG·Takahiro NemotoDaijo Hashimoto
Jan 25, 2002·Annals of the New York Academy of Sciences·A UmarE T Hawk

❮ Previous
Next ❯

Related Concepts

Related Feeds

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.